Results of Operations and Financial Condition On November 2, 2026 , Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exc…

Results of Operations and Financial Condition On August 3, 2026 , Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…

and the copy of the image of the corneal epithelial defect closure from the patent prosecution record that is attached to this Current Report on Form 8-K as Exhibit 99.1 shall not be (i) deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended , or otherwise subject to the liabilities of that section, or (ii) incorporated by reference into any filing with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, re…

Results of Operations and Financial Condition On May 4, 2026 , Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending March 31, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition On February 17, 2026 , Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter and year ending December 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. On January 11, 2026, Krystal Biotech, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”) in advance of (i) the Company’s presentation on January 12, 2026 at the 44 th Annual J.P. Morgan Healthcare Conference (the “Conference”) and (ii) the Company’s participation in the Conference, including management’s discussions with investors and others. The Press Release contains certain preliminary financial informat…

Director — Kirti Ganorkar: A long-serving director is resigning due to personal career advancement at another company, which is a standard board turnover event without negative implications for the company's operations.

Results of Operations and Financial Condition On November 3, 2025, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exch…

Results of Operations and Financial Condition On August 4, 2025, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Ac…

Results of Operations and Financial Condition. On May 6, 2025, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending March 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On February 19, 2025, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter and year ending December 31, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. On November 4, 2024, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exc…

Results of Operations and Financial Condition. On August 5, 2024, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…

Results of Operations and Financial Condition. On May 6, 2024, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending March 31, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operation and Financial Condition. On February 26, 2024, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter and year ended December 31, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On November 6, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On August 7, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a…

Chief Commercial Officer — Andrew Orth: The Chief Commercial Officer resigned from his position, representing the loss of a senior executive.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 21, 2023, Krystal Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing an aggregate of 1,729,729 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”), at a price of $92.50 per share for an aggregate purchase price of approximately $1…

Unregistered Sales of Equity Securities. The information contained in

Other Events In connection with the FDA approval, the Company is filing certain updated risk factors with this Current Report on Form 8-K for the purpose of supplementing and updating disclosures contained in the Company’s prior filings with the SEC, including those discussed under the heading “Risk Factors,” in the Company’s prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, on May 8, 2023 with the SEC. The updated risk factors are filed here…

Regulation FD Disclosure. On May 19, 2023, Krystal Biotech, Inc. (the “Company”) issued a press release announcing U.S. Food and Drug Administration (“FDA”) approval of VYJUVEK TM (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with either recessive or dominant Dystrophic Epidermolysis Bullosa. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company will be hosting an investor conference call and…

Entry into a Material Definitive Agreement. On May 8, 2023, Krystal Biotech, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to issue and sell shares of the Company’s common stock, par value $0.00001 per share, having an aggregate offering price of up to $150.0 million (the “Placement Shares”) from time to time during the term of the Sales Agreement, through an “at-the-market” equity offering program under which Cowen will act…

Results of Operations and Financial Condition. On May 8, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending March 31, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Director — Catherine Mazzacco: The filing discloses the appointment of a new independent director to fill a vacancy created by a board size increase, which is a routine governance action.